WuXi Biologics WKN: A2QJCN ISIN: KYG970081173 Forum: Aktien User: Summer.76

Good News?

🎈

Mit einer Einschätzung zur WuXi im unteren Drittel: https://amp-news.cnyes.com/news/id/5053724

WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers https://www.prnewswire.com/news-releases/wuxi-biologics-and-gsk-enter-into-license-agreement-on-multiple-novel-bi---multi-specific-t-cell-engagers-301713506.html • WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell engaging (TCE) antibody and the option of three additional bi-/multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms • WuXi Biologics will receive an upfront payment of $40 million and tiered royalties on net sales

JPM's Long Position In Wuxi Biologics Rises To 7.03% - HKEx Filing https://kalkinemedia.com/cn/business-news/pharma/brief-jpms-long-position-in-wuxi-biologics-rises-to-703-hkex-filing

"Reputable Report" Citigroup: The current level is a good time to buy the healthcare sub-sector, WuXi Biologics (02269 HK), Zhongsheng Pharmaceutical (01177 HK), Sinopharm (01099 HK), etc. http://www.aastocks.com/tc/stocks/news/aafn-news/NOW.1236181/2

https://amp-news.cnyes.com/news/id/5051081

https://www.wuxibiologics.com/wuxi-biologics-received-first-gmp-certificate-of-ireland-site-from-ireland-health-products-regulatory-authority/

https://www.quamnet.com/post/dvWutYOWLMlBji43kxTcU KGI: WuXi Biologics (02269) Target Price 68 Yuan Stop Loss Price 47 Yuan

WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List https://www.prnewswire.com/news-releases/wuxi-biologics-shanghai-co-ltd-removed-from-the-us-commerce-departments-unverified-list-301704805.html

https://www.reuters.com/business/healthcare-pharmaceuticals/us-commerce-removes-wuxi-biologics-unverified-list-2022-12-15/

http://www.aastocks.com/tc/stocks/news/aafn-news/NOW.1232017/2

Kehrtwende bei Morgan Stanley Peking lockert – Bei diesen China-Aktien sind Analysten bullish https://www.wallstreet-online.de/_amp/nachricht/16297728-kehrtwende-morgan-stanley-peking-lockert-china-aktien-analysten-bullish

https://endpts.com/big-pharmas-team-up-with-local-singapore-organizations-to-boost-manufacturing/

Capital Group: Was hilft gegen die aktuelle Schwäche chinesischer Gesundheitsaktien? https://www.fundresearch.de/amp/capital-group-was-hilft-gegen-die-aktuelle-schwaeche-chinesischer-gesundheitsaktien-454222

https://finance.sina.cn/hkstock/ggpj/2022-12-01/detail-imqmmthc6637583.d.html?from=wap CITIC Securities: WuXi Biologics (02269) was first given a "buy" rating with a target price of HK$67